Global oncology company BeOne Medicines (previously known as BeiGene) is expanding its manufacturing and research and development (R&D) facility in New Jersey, US, to add small molecule manufacturing capacity.
The project, with an estimated investment of $300m (SFr242.2m), will increase the company’s capacity to produce its medicines and support the further development of its oncology portfolio, which includes more than 35 clinical and commercial-stage assets.
Recommended Buyers Guides
BeOne announced the project in July 2026. Construction on the facility is expected to commence in October 2026.
The expanded facility is scheduled to be fully operational in 2029. It will be operated by BeOne’s manufacturing subsidiary, BeOne Medicines US Manufacturing.
The plant is expected to produce around 75 million tablets per year initially, with the capacity to expand to roughly 225 million tablets annually if market demand rises.
Around 120 additional full-time positions are expected to be created by the project, taking the site’s total workforce to nearly 240. With this latest project, BeOne’s cumulative manufacturing investment in the US will exceed $1bn.
Location
The new small-molecule pharmaceutical manufacturing facility will be constructed adjacent to BeOne’s existing clinical and commercial-stage plant at the Princeton West Innovation Campus in Hopewell, New Jersey, which serves as the company’s principal US manufacturing and clinical R&D hub.
Located on a 42-acre site, the campus commenced operations in July 2024 following an initial investment of $800m. It offers more than one million square feet (ft²) of developable space to accommodate future expansion.
In addition to the planned small molecule capabilities, the site currently supports clinical and commercial-scale biologics manufacturing for BeOne’s solid tumour portfolio.
BeOne manufacturing facility and R&D centre expansion details
BeOne’s manufacturing and R&D facility expansion will involve the construction of a new three-storey building spanning approximately 145,000ft² (13,470m²), increasing the overall campus footprint to around 545,000ft².
The building’s core production areas, spanning 48,220ft², will initially accommodate a single small molecule manufacturing line dedicated to high‑efficiency oral solid dose manufacturing, with additional space configured to support two additional lines.
The remaining 96,440ft2 will be allocated to plant utilities, laboratory suites, office and administrative space, storage and warehousing, along with areas reserved for future growth.
The facility is expected to handle all key unit operations associated with tablet manufacture, including blending, granulation and fluid-bed drying, as well as tableting, coating and packaging. It will consolidate drug product manufacturing and packaging activities, enhancing BeOne’s production and supply chain capabilities for its haematology portfolio and pipeline.
esigned in line with current US Food and Drug Administration and Good Manufacturing Practices requirements, the facility will make use of the campus’ established utilities, logistics infrastructure and operating framework.
Project benefits
The enlarged site is intended to strengthen and provide greater operational flexibility to support collaborations with external partners and facilitate BeOne’s global ‘development highway’, a fully in-house platform spanning clinical development, regulatory affairs and manufacturing.
This strategically positioned approach brings together one of the sector’s largest oncology research groups with close to 6,000 colleagues across clinical development and manufacturing, helping to cut both the time and cost of delivering new cancer medicines worldwide.
The expansion is expected to underpin the company’s pipeline programmes across several haematological malignancies, alongside solid tumours including breast, gynaecological, lung, liver and gastrointestinal cancers, among others. These efforts cover a range of advanced modalities such as small molecules, biologics, targeted protein degraders, multi-specific antibodies and antibody-drug conjugates.
Following the expansion, the Princeton West Innovation Campus is set to function as a fully integrated, multi-platform manufacturing hub, combining existing biologics capabilities with the new small molecule drug product operations.
Incentives
The expansion is supported by the New Jersey Economic Development Authority (NJEDA) Board through the Next New Jersey Manufacturing Program, which is designed to enhance the state’s manufacturing and pharmaceutical base and promote employment growth.
Under this programme, BeOne is eligible for incentives totalling $33.9m over five years.
Marketing commentary on BeOne
BeOne Medicines focuses on the discovery and development of therapies for cancer patients worldwide.
The company’s portfolio covers both haematological malignancies and solid tumours, and the company advances a broad pipeline of novel therapeutics using a combination of in-house capabilities and external collaborations. Its oncology therapies have been provided to more than two million patients globally, according to the company.
Headquartered in Switzerland, the company employs more than 12,000 people across six continents, including more than 2,000 based in the US. In 2025, the company reported revenues of $5.3bn and a workforce of 11,000.
